ClinicalTrials.gg
CompletedNCT03046056DIVERGENCE 1Updated Aug 23, 2021Results posted

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Small Bowel Crohn's Disease, sponsored by Gilead Sciences. Completed at 38 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-23.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
230th of 528
78 · median 60
Started
2017
with 36 others
Phase 2
141 of 660
23 open now
Registered
334th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 230th largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 141 in phase 2, and was the 334th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission defined as Crohn's disease activity index (CDAI) \< 150, at Week 24 in participants with small bowel Crohn's disease (CD). Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

03

Conditions studied

  • Small Bowel Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males or non-pregnant, nonlactating females, ages 18 to 75 years, inclusive based on the date of screening visit
  • Moderately or severely active CD
  • Minimum duration of CD of at least 6 months
  • Presence of diseased small bowel (SB) segments in at least 1 of the following segments: terminal ileum, distal ileum, or jejunum
  • Patients with additional colonic involvement of CD are permitted in study as long as SBCD is present
  • Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines):

    • Immunomodulators
    • Tumor necrosis factor-alpha (TNFα) antagonists
    • Vedolizumab
    • Ustekinumab
  • Willing and able to undergo magnetic resonance enterography (MRE) per protocol requirements

Key Exclusion Criteria:

  • Presence of symptomatic or (eg, obstructive or symptomatic) strictures or stenosis.
  • Presence of fistulae
  • Evidence of short bowel syndrome
  • Presence of ulcerative colitis, indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon
  • History of total colectomy, subtotal-colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study
  • Use of any prohibited concomitant medications as described in the study protocol
  • Active tuberculosis (TB) or history of latent TB that has not been treated

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Experimental
    Filgotinib 100 mg

    Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Placebo comparator
    Placebo

    PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.

    Drug: Placebo to match filgotinib

Interventions

  • Tablet(s) administered orally once daily

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo to match filgotinib

    Tablet(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 24

    The CDAI score is used to quantify the symptoms of participants with Crohn's Disease (CD). The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24

    Magnetic resonance enterography (MRE) is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and relative contrast enhancement (RCE). A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these components for the terminal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.

    Time frame: Baseline; Week 24

  2. Change From Baseline in Distal Ileum Segmental MaRIA Score at Week 24

    MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.

    Time frame: Baseline; Week 24

  3. Change From Baseline in Jejunum Segmental MaRIA Score at Week 24

    MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system.The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A positive change from baseline indicates disease worsening.

    Time frame: Baseline; Week 24

  4. Percentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in terminal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

    Time frame: Week 24

  5. Percentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in distal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

    Time frame: Week 24

  6. Percentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in jejunum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

    Time frame: Week 24

  7. Percentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ minimum detectable difference (MDD) units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the terminal ileum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

    Time frame: Week 24

  8. Percentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score≥ 7 in the distal ileum. For segments with baseline MaRIA score ≥ 15, the minimum detectable difference (MDD) is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

    Time frame: Week 24

  9. Percentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the jejunum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

    Time frame: Week 24

  10. Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Small bowel MaRIA remission was defined as MaRIA score \< 7 at Week 24 in each of the 3 small bowel segments, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.

    Time frame: Week 24

  11. Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 24

    The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Participant level small bowel MaRIA response was defined as all small bowel segments with baseline MaRIA score ≥7 achieve segment level MaRIA response, with no segment level disease worsening in any other segment(s) at Week 24, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.

    Time frame: Week 24

  12. Percentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10

    The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.

    Time frame: Week 10

  13. Change From Baseline in CDAI Scores at Week 10

    The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement.

    Time frame: Baseline; Week 10

  14. Change From Baseline in CDAI Scores at Week 24

    The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement.

    Time frame: Baseline; Week 24

07

Results

Posted Aug 9, 2021

Participant flow

Participants were enrolled at study sites in the United States, Canada, and Europe. The first participant was screened on 11 April 2017. The last study visit occurred on 20 July 2020.

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mgPlacebo
Started283218
Completed161611
Not completed12167
Withdrew: Non-responder at week 10664
Withdrew: Protocol-specified disease worsening331
Withdrew: Adverse event150
Withdrew: Non-compliance with study drug002
Withdrew: Protocol violation110
Withdrew: Investigator's discretion010
Withdrew: Withdrew consent100

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission at Week 24

The CDAI score is used to quantify the symptoms of participants with Crohn's Disease (CD). The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Clinical Remission at Week 2425.0 (12.4 to 41.9)25.0 (13.1 to 40.6)16.7 (4.7 to 37.7)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 8.3 · 90% CI -16.5 to 32.1
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: 8.3 · 90% CI -15.9 to 32.0
SecondaryChange From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24

Magnetic resonance enterography (MRE) is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and relative contrast enhancement (RCE). A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these components for the terminal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24
score on scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Change From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24-1.8 ± 1.510.7 ± 1.390.5 ± 1.64
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Least squares mean difference: -2.3 · 90% CI -5.3 to 0.7
  • Filgotinib 100 mg vs Placebo · Least squares mean difference: 0.2 · 90% CI -2.7 to 3.1
SecondaryChange From Baseline in Distal Ileum Segmental MaRIA Score at Week 24

MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in Distal Ileum Segmental MaRIA Score at Week 24
score on scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Change From Baseline in Distal Ileum Segmental MaRIA Score at Week 24-1.1 ± 1.12-0.5 ± 1.080.5 ± 1.26
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Least squares mean difference: -1.6 · 90% CI -3.9 to 0.7
  • Filgotinib 100 mg vs Placebo · Least squares mean difference: -1.0 · 90% CI -3.2 to 1.2
SecondaryChange From Baseline in Jejunum Segmental MaRIA Score at Week 24

MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system.The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A positive change from baseline indicates disease worsening.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in Jejunum Segmental MaRIA Score at Week 24
score on scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Change From Baseline in Jejunum Segmental MaRIA Score at Week 240.4 ± 1.000.6 ± 0.950.5 ± 1.12
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Least squares mean difference: -0.1 · 90% CI -2.2 to 2.0
  • Filgotinib 100 mg vs Placebo · Least squares mean difference: 0.1 · 90% CI -1.9 to 2.0
SecondaryPercentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in terminal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 244.5 (0.2 to 19.8)6.7 (1.2 to 19.5)6.3 (0.3 to 26.4)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: -1.7 · 90% CI -28.6 to 25.5
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: 0.4 · 90% CI -24.5 to 26.2
SecondaryPercentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in distal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 2410.0 (0.5 to 39.4)0 (0.0 to 31.2)16.7 (0.9 to 58.2)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: -6.7 · 90% CI -47.3 to 37.0
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: -16.7 · 90% CI -58.2 to 30.0
SecondaryPercentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in jejunum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 2433.3 (6.3 to 72.9)0 (0.0 to 31.2)0 (0.0 to 63.2)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 33.3 · 90% CI -32.4 to 86.5
SecondaryPercentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ minimum detectable difference (MDD) units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the terminal ileum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 2422.7 (9.4 to 42.0)10.0 (2.8 to 23.9)25.0 (9.0 to 48.4)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: -2.3 · 90% CI -28.6 to 24.3
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: -15.0 · 90% CI -39.4 to 11.3
SecondaryPercentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score≥ 7 in the distal ileum. For segments with baseline MaRIA score ≥ 15, the minimum detectable difference (MDD) is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 2420.0 (3.7 to 50.7)12.5 (0.6 to 47.1)16.7 (0.9 to 58.2)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 3.3 · 90% CI -38.9 to 45.7
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: -4.2 · 90% CI -47.5 to 40.8
SecondaryPercentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the jejunum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 2450.0 (15.3 to 84.7)12.5 (0.6 to 47.1)0 (0.0 to 63.2)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 50.0 · 90% CI -16.8 to 89.5
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: 12.5 · 90% CI -46.1 to 63.3
SecondaryPercentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Small bowel MaRIA remission was defined as MaRIA score \< 7 at Week 24 in each of the 3 small bowel segments, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 248.0 (1.4 to 23.1)6.3 (1.1 to 18.4)0 (0.0 to 15.3)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 8.0 · 90% CI -17.2 to 32.6
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: 6.3 · 90% CI -18.1 to 30.2
SecondaryPercentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 24

The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Participant level small bowel MaRIA response was defined as all small bowel segments with baseline MaRIA score ≥7 achieve segment level MaRIA response, with no segment level disease worsening in any other segment(s) at Week 24, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 2420.0 (8.2 to 37.5)12.5 (4.4 to 26.4)16.7 (4.7 to 37.7)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 3.3 · 90% CI -22.1 to 28.1
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: -4.2 · 90% CI -28.1 to 20.3
SecondaryPercentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10

The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgPlacebo
Percentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 1039.3 (23.8 to 56.5)25.0 (13.1 to 40.6)22.2 (8.0 to 43.9)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Risk difference in proportions: 17.1 · 90% CI -7.6 to 40.4
  • Filgotinib 100 mg vs Placebo · Risk difference in proportions: 2.8 · 90% CI -21.2 to 26.5
SecondaryChange From Baseline in CDAI Scores at Week 10

The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement.

Time frame:
Baseline; Week 10
Reported as:
Least squares mean · score on scale
Change From Baseline in CDAI Scores at Week 10
score on scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Change From Baseline in CDAI Scores at Week 10-105 ± 23.6-88 ± 22.3-57 ± 26.2
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Least squares mean difference: -48 · 90% CI -95 to -1
  • Filgotinib 100 mg vs Placebo · Least squares mean difference: -31 · 90% CI -76 to 15
SecondaryChange From Baseline in CDAI Scores at Week 24

The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on scale
Change From Baseline in CDAI Scores at Week 24
score on scaleFilgotinib 200 mgFilgotinib 100 mgPlacebo
Change From Baseline in CDAI Scores at Week 24-86 ± 24.1-71 ± 22.8-66 ± 26.7
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Least squares mean difference: -20 · 90% CI -68 to 28
  • Filgotinib 100 mg vs Placebo · Least squares mean difference: -5 · 90% CI -52 to 42

Adverse events

Collected over All-Cause Mortality: First dose date up to last dose date (maximum: 28.7 weeks) plus 59 days; Adverse Events: First dose date up to last dose date (maximum: 28.7 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg1/28 (3.6%)4/28 (14.3%)20/28 (71.4%)
Filgotinib 100 mg0/32 (0%)7/32 (21.9%)24/32 (75%)
Placebo0/18 (0%)0/18 (0%)13/18 (72.2%)
Most frequent serious events
Most frequent serious events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
Crohn's diseaseGastrointestinal disorders2/284/320/18
Small intestinal obstructionGastrointestinal disorders2/280/320/18
IleusGastrointestinal disorders0/281/320/18
Anal abscessInfections and infestations0/281/320/18
PneumoniaInfections and infestations0/281/320/18
Most frequent other events
Showing 10 of 46
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mgPlacebo
Abdominal painGastrointestinal disorders5/286/321/18
Crohn's diseaseGastrointestinal disorders4/286/322/18
NauseaGastrointestinal disorders5/283/321/18
SinusitisInfections and infestations4/280/321/18
HeadacheNervous system disorders4/284/322/18
NasopharyngitisInfections and infestations0/284/320/18
VomitingGastrointestinal disorders1/282/322/18
Muscle spasmsMusculoskeletal and connective tissue disorders0/281/322/18
DizzinessNervous system disorders1/282/322/18
InfluenzaInfections and infestations3/281/320/18

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Mean46 ± 16.342 ± 12.945 ± 12.944 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Female1923951
Male99927
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Race — American Indian or Alaska Native0000
Race — Asian0000
Race — Black or African American2428
Race — Native Hawaiian or Pacific Islander0000
Race — White25281669
Race — Other1001
Race — Not Permitted0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Ethnicity — Not Hispanic or Latino26311774
Ethnicity — Hispanic or Latino2114
Ethnicity — Not Permitted0000
Region of Enrollment
Region of Enrollment(participants)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
United States15131038
Hungary0314
Czechia0101
Ukraine2013
United Kingdom4127
Spain1203
Canada0415
Austria1102
Belgium0202
Italy3115
France2215
Germany0213
Crohn's Disease Activity Index Score (CDAI)
Crohn's Disease Activity Index Score (CDAI)(score on scale)Filgotinib 200 mgFilgotinib 100 mgPlaceboTotal
Mean309 ± 55.7297 ± 64.9300 ± 63.7302 ± 60.9
08

Study locations

38 sites
  • University of Miami Crohn's and Colitis Center
    Miami, Florida 33136, United States
  • Center for lnterventional Endoscopy- Florida Hospital
    Orlando, Florida 32804, United States
  • University of South Florida South Tampa campus
    Tampa, Florida 33606, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • Fargo Gastroenterology and Hepatology Clinic
    Fargo, North Dakota 58103, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • TDDC San Marcos
    San Marcos, Texas 78666, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Medical University of Innsbruck, Department of Internal Medicine I
    Innsbruck, 6020, Austria
  • Medical University of Vienna, Department of Internal Medicine III, Division Gastroenterology and Hepatology
    Vienna, 1090, Austria
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Centre Hospitalier Chretien
    Liège, 4000, Belgium
  • Mount Sinai Hospital
    Toronto, M5T 3L9, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, V8V 3M9, Canada
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 500 12, Czechia
  • CHU de Toulouse -Hopital Rangueil (Main Office)
    Toulouse Cedex 9, Midi-Pyrenees 31059, France
  • Gastroenterologie, Hepatologie und Endokrinologie
    Hannover, 30625, Germany
  • Universitatsklinikum Jena
    Jena, 07747, Germany
  • Bugát Pál Kórház, Gasztroenterológiai osztály
    Gyöngyös, Heves 3200, Hungary
  • Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórháza
    Békéscsaba, 5600, Hungary
  • Azienda Ospedaliero - Universitaria Mater Domini
    Catanzaro, 88100, Italy
  • Gastroenterologia, Policlinico Universitario Campus Bio-Medico di Roma
    Rome, 00128, Italy
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario Gran Canaria Dr. Negrin
    Las Palmas De Gran Canaria, 35016, Spain
  • Ivano-Frankivsk Central City Clinical Hospital, Department of Therapy #1, SHEI Ivano-Frankivsk National Medical University
    Ivano-Frankivsk, 76018, Ukraine
  • Communal Healthcare Institution Regional Hospital of War Veterans, Department of Therapy #1
    Kharkiv, 61137, Ukraine
  • Communal Institution of Ternopil Regional Council Ternopil University Hospital. Regional Center of Gastroenterology
    Ternopil, 46002, Ukraine
  • Queen Elizabeth University Hospital
    Glasgow, Scotland G51 4TF, United Kingdom
  • Royal Devon and Exeter Hospital, Department of Gastroenterology
    Exeter, EX2 5DW, United Kingdom
  • St Georges Clinical Research Facility
    London, SW17 0QT, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Riviere P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol. 2021 Jan 1;116(1):134-141. doi: 10.14309/ajg.0000000000000834. PubMed 33177349 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jul 2020, 39 months.

Results were first posted in Aug 2021, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 39 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2017
First posted
Feb 8, 2017
StartActual
Apr 11, 2017
Primary completionActual
Jul 20, 2020
CompletionActual
Jul 20, 2020
Results first posted
Aug 9, 2021
Last update
Aug 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03046056
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Feb 8, 2017
Start date
Apr 11, 2017
Primary completion
Jul 20, 2020
Completion
Jul 20, 2020
Results posted
Aug 9, 2021
Last update
Aug 23, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion